
bostonheart diagnostic

FINAL REPORT



Glucose ²	84			74
	70-99	100-125	<70 or >125 mg/dL	
Adiponectin ¹	11.5			13.4
	>10	7-10	<7 µg/mL	

CLIA# 22D2100622

BHD-REP-003.03

Specimen: Red/yellow Z clot SST received unspun

NYSDOH: 9021

200 Crossing Blvd. Framingham, MA 01702, 508.877.8711



bost conheart

FINAL REPORT

Patient ID:	Gende	r: M		Accession No: C0292661 Report Date & Time: 10.26.2020 1:26 PM	
Test Name	Optimal	Borderline	Increased Risk	Interpretation Footnote	Previous Results 10.20.20
ÖBoston Heart Fat	tty Acid Ba	lance [™] Test¹			
Saturated Fatty Acid Index			34.0	Saturated FA Index is HIGH. Higher levels of plasma saturated fatty acids are associated with an increased risk of CVD. Consider restricting dietary intake of saturated fat by choosing poultry without skin, fish, low fat dairy products, and lean cuts of meat, and replacing	30.1
	<30.0	30.0-33.0	>33.0 %	butter with plant based oils. Consider reducing endogenous (infernal) production of saturated fat by losing weight if appropriate, limiting added sugars, refined starches, and alcohol.	
Trans Fatty Acid Index	0.43			Trans FA Index is OPTIMAL.	0.31
	<0.50	0.50-0.70	>0.70 %	Linesh under d Ophiumbod Datia in LOW A Jaward Linesh under d Ophiumbod	
Unsaturated/Saturated Ratio	0.05	0.00.0.05	1.90	Unsaturated/Saturated Ratio is LOW. A lower Unsaturated/Saturated Ratio Index is associated with a higher LDL-C and increased risk of CVD. Consider increasing intake of plant based fats from nuts, seeds, and their oils along with fatty fish and restrict intake of animal fats like	2.29
Omene O Fetty Asid	>2.25	2.00–2.25	<2.00	red meat, fatty processed meats, and full fat dairy.	-
Omega-3 Fatty Acid Index		4.40		Omega-3 FA Index is BORDERLINE. A lower Omega-3 FA index is associated with an increased risk for CVD. Eicosapentaenoic Acid (EPA) level is BORDERLINE. Increased EPA levels have been associated with lower risk of heart disease. Docosahexaenoic Acid (DHA) level is OPTIMAL. The Omega-3 FA Index is the amount of EPA and DHA divided by total fatty acids. Consider recommending consumption of at least 2-3 meals of oily fish such as salmon.	3.54
- DA	>4.50	2.50-4.50	<2.50 %	ADHA) level is OPTIMAL. The Omega-3 FA Index is the amount of EPA and DHA divided by total fatty acids. Consider recommending	
EPA	. 50.0	36.5 20.0-50.0		consumption of at least 2-3 meals of oily fish such as salmon, sardines, herring, tuna, and mackerel weekly or a fish oil or EPA	
DHA	>50.0 105.1	20.0-30.0	<20.0 µg/mL	supplement.	
DIA	>105.1	60.0-100.0	<60.0 µg/mL	-	
ALA	>100.0	00.0-100.0	<00.0 µg/m∟ 10.1	Alpha Linolenic Acid (ALA) level is LOW. High levels of ALA have been associated with a lower risk of CVD. Consider recommending	8.0
	>30.0	14.0–30.0	-14.0 μg/mL	associated with a lower risk of CVD. Consider recommending increasing intake of walnuts, chia seeds, ground flaxseeds, or flaxseed oil.	0.0
EPA/AA Ratio		0.12		EPA/AA Ratio is BORDERLINE. Some authorities indicate that an EPA/AA ratio of >0.75 is optimal, usually only achieved with	0.09
	>0.17	0.07-0.17	<0.07	supplementation.	
AA/EPA Ratio		8.15		AA/EPA Ratio is BORDERLINE. Some authorities indicate that an AA/EPA ratio of <1.33 is optimal, usually only achieved with	11.64
	<5.88	5.88-14.29	>14.29	supplementation.	
	Low	Mid	High		
Monounsaturated Fatty Acid Index			26.0	Values are reported according to the lowest, middle and highest thirds of our reference population. Dietary monounsaturated fats from plant sources reduce heart disease risk; however, blood levels of monounsaturated fats do not necessarily correlate closely with dietary	31.2
	<20.0	20.0-23.0	>23.0 %	intake. More data are needed on the complex effects of omega-6 fatty acids on cardiovascular risk.	
Omega-6 Fatty Acid Index	34.3				34.3
	<39.0	39.0-43.0	>43.0 %	-	
Linoleic Acid (LA)	774.8	000 0 1150 5	4450.0	-	874.6
Arochidania Asid (AA)	<930.0	930.0-1150.0	>1150.0 µg/mL	-	001 1
Arachidonic Acid (AA)	<250.0	297.6 250.0-320.0	>320.0 µg/mL	-	331.1
Omega-3/Omega-6 Ratio	<200.0	200.0-320.0	>320.0 µg/mL		0.11
nauo	<0.07	0.07-0.10	>0.10	-	

CLIA# 22D2100622 BHD-REP-003.03



bost conheart

FINAL REPORT

C		Gender: M	a				cim	on No: CO2926 Date & Time: 1C	61 .26.2020 1:26	PM				
Test Name	Low	Normal	High	Footnotes	Previous Results 10.20.20	Test Name	Low	Normal	High	Footnotes	Previous Results 10.20.20			
Chemistry Tests	;					Other Kidney T	ests							
BUN		16.0			16.9	Phosphorus		3.3			3.4			
	<3.0	3.0-25.0	>25.0 mg/dL	1			<2.5	2.5-4.5	>4.5 mg/dL					
Creatinine		1.15			1.17	Test Name	Optimal	Borderline	Increased Risk	Footnotes	Previous			
[<0.67	0.67-1.17	>1.17 mg/dL				10.0				Results 10.20.20			
Sodium		139			140	BUN/Creatinine	13.9				14.4			
	<135	135-146	>146 mmol/L	1			<=23		>23					
Potassium		4.3			4.5	eGFR / Non-African	78				76			
	<3.5	3.5-5.3	>5.3 mmol/L			American								
Chloride		101			102					>60	30-60	<30 mL/min/1.73		
	<98	98-110	>110 mmol/L	1			>00	30-00	m2/mm/1.73					
CO,		23			23	eGFR / African					-			
	<20	20-31	>31 mmol/L	-		American	90				88			
Anion Gap	~20	15	201 minol/E		15	American			<30					
Amon dap	<3	3-16	>16 mmol/L		13		>60	30-60	mL/min/1.73					
Total Protein	<.5	7.2			7.3				m²					
	<6.3	6.3-7.7	>7.7 g/dL	-	7.5					L				
Albumin	<0.5	4.8	>1.1 y/uL		4.8									
	-0.5	4.0 3.5-5.2	>5.2 g/dL	-	4.0									
Coloium	<3.5	9.7	>0.2 y/uL		9.8									
Calcium	-0.0	9.7 8.6-10.4	. 10.4 mm/dl	-	9.0									
Total Dilimitia	<8.6	-	>10.4 mg/dL		0.7									
Total Bilirubin		0.7	. 1.0 mm/dl		0.7									
		0.0–1.2	>1.2 mg/dL											
Direct Bilirubin		0.1			0.2									
Test Name	Optimal	0.0-0.3 Borderline	>0.3 mg/dL Increased Risk	Footnotes	Previous Results									
	0.1				Results 10.20.20									
Glucose ²	84		70 - 105		74									
	70-99	100-125	<70 or >125											
ACT	04		mg/dL		22									
AST	24	40 100	>12011/											
A1 T	<40	40-120	>120 U/L		22									
ALT	25	40 100	> 100 11/1											
AU 1	<40	40-120	>120 U/L											
Alkaline Phosphatase	57				56									
	<130	130-200	>200 U/L											



bost onheart

FINAL REPORT

0		Gender: M	٩.		
Test Name	Low	Optimal	High	Footnotes	Previous Results 10.20.20
Thyroid Tests					
TSH		2.78		9	2.44
	<0.27	0.27-4.2	>4.2 µlU/mL		
Total T4		6.5		10	6.5
	<4.5	4.5-11.7	>11.7 ug/dL		
Free T4		1.54		10	1.39
	<0.93	0.93-1.70	>1.70 ng/dL		
Total T3		0.8		10	0.9
	<0.8	0.8-2.0	>2.0 ng/mL	-	
Free T3		2.6		10	2.6
	<2.0	2.0-4.4	>4.4 pg/mL		

Accession No: C0292661

Specimen

Report Date & Time: 10.26.2020 1:26 PM



bost onheart

θ

FINAL REPORT

Accession No: C0292661

Specimen

Report Date & Time: 10.26.2020 1:26 PM

For comparison purposes only. Refer to	the previous r	eports for comple	ete results.*				
Test Name	10.12.2020	10.20.2020	10.26.2020 (Current)	Test Name	10.12.2020	10.20.2020	10.26.2020 (Current)
ÖBoston Heart HDL M	ap® Test	1,6		Chemistry Tests			<u>`</u>
α-1	28.1	28.7	39.0	BUN	18.4	16.9	16.0
α-2	61.9	61.8	60.6	Creatinine	1.14	1.17	1.15
α-3	18.9	20.4	13.8	Sodium	142	140	139
α-4	15.8	14.2	11.1	Potassium	4.3	4.5	4.3
preβ–1	11.4	7.4	15.4	Chloride	106	102	101
Ö Boston Heart Choles	sterol Ba	lance®Tes	t ¹	CO2	24	23	23
Lathosterol	86	108	116	Anion Gap	12	15	15
Desmosterol	87	98	81	Total Protein	7.0	7.3	7.2
Beta-sitosterol	70	62	37	Albumin	4.5	4.8	4.8
Campesterol	122	55	39	Calcium	9.3	9.8	9.7
Inflammation and Oxid	ation Tes	sts		Total Bilirubin	0.5	0.7	0.7
hs-CRP	4.2	1.4	1.6	Direct Bilirubin	0.1	0.2	0.1
OxPL-apoB ¹	1.4	3.8	2.0	Glucose ²	93	74	84
Metabolic Tests				AST	23	22	24
Glucose ²	93	74	84	ALT	24	22	25
Adiponectin ¹	14.0	13.4	11.5	Alkaline Phosphatase	53	56	57
[↔] Boston Heart Fatty A	cid Bala	nce™ Test¹		Other Kidney Tests			
Saturated Fatty Acid Index	27.6	30.1	34.0	Phosphorus	3.4	3.4	3.3
Trans Fatty Acid Index	0.55	0.31	0.43	BUN/Creatinine	16.1	14.4	13.9
Unsaturated/Saturated Ratio	2.55	2.29	1.90	eGFR / Non-African American	78	76	78
Omega-3 Fatty Acid Index	1.73	3.54	4.40	eGFR / African American	91	88	90
EPA	<15.6	28.4	36.5	Thyroid Tests			
DHA	39.8	98.3	105.1	TSH	2.04	2.44	2.78
ALA	8.4	8.0	10.1	Total T4	6.4	6.5	6.5
EPA/AA Ratio	0.03	0.09	0.12	Free T4	1.57	1.39	1.54
AA/EPA Ratio	30.79	11.64	8.15	Total T3	1.1	0.9	0.8
Monounsaturated Fatty Acid Index	24.0	31.2	26.0	Free T3	3.4	2.6	2.6
Omega-6 Fatty Acid Index	45.5	34.3	34.3				
Linoleic Acid (LA)	964.2	874.6	774.8				
Arachidonic Acid (AA)	340.2	331.1	297.6				
Omega-3/Omega-6 Ratio	0.04	0.11	0.14				
1			<u></u>				

CLIA# 22D2100622 BHD-REP-003.03

Ent f. Shayh

bostönheart

FINAL REPORT

					Accession No: C0292661
e	Gender: M	٩	Specir	20	Report Date & Time: 10.26.2020 1:26 PM
				1	
Tre	atment Consideration Summary				

The intended use of this report is to provide an aid in the physician's treatment decisions. This report is intended for a physician or other qualified health care provider. Please consult with your physician regarding any questions.

	Lifestyle and Dietary Modification	Statins	Niacin	Omega-3 Fatty Acids
Inflammation Tests				
hs-CRP	•	•	•	•
Fatty Acid Balance Test	_			
Unsat/Sat Ratio	•			•
Omega-3 FA Index	•			•
EPA	•			•

Lifestyle and Dietary Modification

Therapeutic lifestyle change is the cornerstone for reducing risk for Cardiovascular Disease (CVD) and diabetes.

The following recommendations are based on the American Heart Association's dietary and lifestyle guidelines. Consume a dietary pattern that achieves <6% of calories from saturated fat and emphasizes intake of vegetables, fruits and whole grains; includes low-fat dairy products, poultry, fatty fish, legumes, non-tropical vegetable oils and nuts; and limits intake of refined grains, sweets, sugar-sweetened beverages and red meats. Eliminate foods high in trans fat.

If indicated: control blood pressure, reduce weight, engage in smoking cessation and be physically active — work up to getting at least 30 minutes of a moderate intensity physical activity, at least 5 days per week.

To improve Fatty Acid Balance results refer to the dietary changes provided in the Fatty Acid Balance interpretation section of this report.

Statins

According to studies, statins have been shown to reduce cholesterol production, increase LDL clearance and lower the risk of CVD and its progression. Statins can lower CoQ10 levels.

Statins:

lowering CRP with statin therapy has been shown to lower CVD events. Elevated CRP may indicate inflammation and CVD risk.

Niacin

Consensus guidelines recommend monitoring glycemic control after initiating niacin (nicotinic acid) treatment or increasing its dosage.

Niacin:

• may decrease CRP by 15-24% in patients with stable coronary artery disease and metabolic syndrome.

Omega-3 Fatty Acids

Studies have shown that Omega-3 Fatty Acids are essential to heart health. Their benefits may include improved cholesterol balance, improved immune system function, reduced inflammation and reduced rates of heart disease.

Omega-3 Fatty Acids:

• Omega-3 fatty acids may lower CRP.

To improve Fatty Acid Balance results focus on the dietary changes provided in the Fatty Acid Balance interpretation section of this report. Consuming 1-2 grams of concentrated fish oil daily or 1800 mg of EPA per day has been shown to decrease heart disease morbidity and mortality.

Notes

The following testing was not completed as it is not performed at BHDx: Leptin, Interleukin-6



FINAL REPORT

	diagnostics®			FINAL
9			men	Accession No: C0292661
	Gender: M	<u>م</u>	Speci	Report Date & Time: 10.26.2020 1:26 PM

Footnotes

bostönheart

The intended use of this report is to provide an aid in the physician's treatment decisions. This report is intended for a physician or other qualified health care provider. Please consult with your physician regarding any questions.

¹ This test was developed and its performance characteristics determined by Boston Heart Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Methods: HDL Map: Gel electrophoresis; Cholesterol Balance and Fatty Acid Balance: GC/MS; MPO: Immunoturbidometric; CoQ10: UPLC; Adiponectin: Latex turbidimetric immunoassay; OxPL-apoB: Chemiluminescent immunoassay; LDL-P: NMR. TMAO, Cortisol, DHEA-S, DHT, Estradiol, Estrone, Progesterone, Total Testosterone, Estriol, 170H Progesterone, Androstenedione: LC/MS/MS.

²A fasting glucose level of >125 mg/dL indicates the presence of diabetes mellitus, and a fasting glucose level of <70 mg/dL indicates hypoglycemia.

³A test result in the low range is normal in a non-diabetic, but low if a patient has diabetes (consistent with diabetes).

⁴Genetic analysis is performed by real time Polymerase Chain Reaction (PCR) using TaqMan• probes. Amplified gene nucleotide sites: APOE - Apolipoprotein E, T471 C rs429358, C609T rs7412; F5 - Coagulation Factor V, G1746A rs6025; F2 - Coagulation Factor 2, G20210A rs1799963; CYP2C19 (Clopidogrel response) -Cytochrome P450 2C19, G681A rs4244275, G636A rs4986893, C-806T rs12248560; SLC01B1 (Statin Myopathy) - Solute Carrier Organic Anion Transporter Family, Member 1B1, T625C rs4149056. MTHFR – Methylenetetrahydrofolate reductase, C677T rs1801133, A1298C rs1801131. Limitations: Other rare mutations not detected by these assays may be present in some individuals.

⁶Test performed at 200 Crossing Boulevard, Framingham, MA 01702. CLIA#: 22D2100622. NYSDOH: 9021.

⁹Biotin concentrations of up to 1200 ng/mL in patient serum have been shown to have no impact on assay results.

¹⁰High doses of biotin (>5mg/day) may interfere with assay results. Patient assumed to be refraining from biotin supplementation for at least 3 days prior to blood draw.

¹¹Our Cholesterol Balance Test was modified on April 1, 2019. This modification has resulted in new reference ranges. Results reported prior to April 1, 2019 should not be compared with results from this date forward.

* Tests performed with alternative methodologies are not displayed for comparative purposes.

🔺 = Critical Value, 🕰 = Alert Value, TNP = Test Not Performed, PEND = Test Result Pending, GSP = Glycated Serum Protein, ADA = American Diabetes Association

©2020 Boston Heart Diagnostics Corporation. All rights reserved. The Boston Heart Diagnostics logo, Boston Heart HDL Map, Boston Heart Cholesterol Balance, Boston Heart Prediabetes Assessment, and Boston Heart Fatty Acid Balance are trademarks or registered trademarks of Boston Heart Diagnostics Corporation. TaqMan[®] is a registered trademark of Roche Molecular Systems, Inc.

